FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Uğur Şahin, Ö. Türeci, Georgy M. Manikhas, Florian Lordick, Andriy Rusyn, Ihor Vynnychenko, Assen Dudov, I. Bazin, Igor Bondarenko, Bohuslav Melichar, Karl Dhaene, Kai Wiechen, Christoph Huber, Daniel Maurus, Ahsan M. Arozullah, J.W. Park, Martin Schüler, S. Al-Batran